More Is Not Better Claudia Andreu-Vieyra, Ph.D and James Berenson, M.D. Multiple myeloma (MM) is the most common primary malignancy of the bone marrow.1, The 5-year survival rate for MM patients has increased from 25% in 1975 to almost 40% due to newer and more effective drugs, such as the immunomodulatory agents (IMiDs) thalidomide and […]
Tag Archives: transplant
James R. Berenson, MD
President and CEO - James R. Berenson, MD, Inc.
Medical & Scientific Director - Institute for Myeloma
& Bone Cancer Research (IMBCR)
Chief Executive Officer - Oncotherapeutics
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- Outcomes in Multiple Myeloma Patients Evaluated
- Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
- Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
- Understanding Myeloma News About Secondary Cancers and Clotting
-
Dedication of “Determination”
April 10, 2014
0 Comments